View ValuationFidia 将来の成長Future 基準チェック /06現在、 Fidiaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長23.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • Oct 02Analysts lower revenue estimates to €26.0mThe 2020 consensus revenue estimate decreased from €33.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.98 for the same period. The Machinery industry in Italy is expected to see a 8.2% decline in net income next year. The consensus price target was lowered from €3.00 to €2.50. Share price is down by 1.2% to €2.43 over the past week.すべての更新を表示Recent updatesNew Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (446% increase in shares outstanding). Market cap is less than US$10m (€189.8k market cap, or US$223.4k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).分析記事 • Sep 26The Market Doesn't Like What It Sees From Fidia S.p.A.'s (BIT:FDA) Revenues Yet As Shares Tumble 27%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 27% in the last thirty days...分析記事 • Aug 01Why Investors Shouldn't Be Surprised By Fidia S.p.A.'s (BIT:FDA) 34% Share Price PlungeFidia S.p.A. ( BIT:FDA ) shares have had a horrible month, losing 34% after a relatively good period beforehand. For...分析記事 • May 26Investors Aren't Buying Fidia S.p.A.'s (BIT:FDA) RevenuesFidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...New Risk • May 23New major risk - Revenue and earnings growthEarnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.5m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€3.88m market cap, or US$4.41m).New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€2.91m market cap, or US$3.25m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 11x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (over 11x increase in shares outstanding). Market cap is less than US$10m (€1.44m market cap, or US$1.63m).Reported Earnings • Oct 25First half 2024 earnings released: €0.21 loss per share (vs €0.30 loss in 1H 2023)First half 2024 results: €0.21 loss per share. Revenue: €9.42m (up 4.8% from 1H 2023). Net loss: €7.22m (loss widened 246% from 1H 2023).分析記事 • Oct 18Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% HidingTo the annoyance of some shareholders, Fidia S.p.A. ( BIT:FDA ) shares are down a considerable 34% in the last month...分析記事 • Aug 29It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It LooksUnfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 40% in the last thirty days...New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.17m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Market cap is less than US$10m (€9.17m market cap, or US$9.96m).分析記事 • Jun 20Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% BounceFidia S.p.A. ( BIT:FDA ) shares have continued their recent momentum with a 28% gain in the last month alone. Still...Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€19.8m market cap, or US$21.3m).Reported Earnings • Jun 09Full year 2023 earnings released: €0.19 loss per share (vs €0.86 profit in FY 2022)Full year 2023 results: €0.19 loss per share (down from €0.86 profit in FY 2022). Revenue: €29.9m (up 21% from FY 2022). Net loss: €1.31m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.分析記事 • May 28Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)Key Insights The projected fair value for Fidia is €0.84 based on 2 Stage Free Cash Flow to Equity Current share price...New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.8m market cap, or US$16.8m).New Risk • Apr 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 349% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€12.0m market cap, or US$12.8m).New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 37% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (€3.10m market cap, or US$3.34m). Minor Risk Shareholders have been diluted in the past year (37% increase in shares outstanding).分析記事 • Feb 13Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 31% in the last thirty days...分析記事 • Dec 23Is Fidia (BIT:FDA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Oct 04Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren'tThere wouldn't be many who think Fidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.6% operating cash flow to total debt). High level of non-cash earnings (96% accrual ratio). Market cap is less than US$10m (€9.01m market cap, or US$9.81m). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Shareholders have been diluted in the past year (36% increase in shares outstanding).Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Is New 90 Day High Low • Feb 13New 90-day high: €2.74The company is up 6.0% from its price of €2.58 on 13 November 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 15% over the same period.Is New 90 Day High Low • Dec 30New 90-day low: €1.43The company is down 42% from its price of €2.46 on 01 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.Is New 90 Day High Low • Dec 07New 90-day low: €2.08The company is down 22% from its price of €2.67 on 08 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 20New 90-day low: €2.15The company is down 22% from its price of €2.77 on 21 August 2020. The Italian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 14New 90-day low: €2.30The company is down 16% from its price of €2.73 on 16 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 19% over the same period.Major Estimate Revision • Oct 02Analysts lower revenue estimates to €26.0mThe 2020 consensus revenue estimate decreased from €33.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.98 for the same period. The Machinery industry in Italy is expected to see a 8.2% decline in net income next year. The consensus price target was lowered from €3.00 to €2.50. Share price is down by 1.2% to €2.43 over the past week.Is New 90 Day High Low • Sep 28New 90-day low: €2.40The company is down 16% from its price of €2.86 on 30 June 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €3.72m, with losses widening by 47% from the prior year. Total revenue was €38.1m over the last 12 months, down 31% from the prior year.お知らせ • Sep 05Fidia S.p.A. to Report First Half, 2020 Results on Sep 11, 2020Fidia S.p.A. announced that they will report first half, 2020 results on Sep 11, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Fidia は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BIT:FDA - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202521-2-5-5N/A3/31/202519-6-5-5N/A12/31/202418-9-4-4N/A9/30/202424-8-3-3N/A6/30/202430-6-8-8N/A3/31/202429-4-7-6N/A12/31/202329-1-5-5N/A9/30/202326-3-1-1N/A6/30/202324-533N/A3/31/202324122N/A12/31/202225601N/A12/31/202124-301N/A12/31/202022-634N/A6/30/202038-445N/A3/31/202043-456N/A12/31/201946-423N/A9/30/201957-202N/A6/30/201955-3-6-4N/A3/31/201961-1N/A-5N/A12/31/201859-1N/A-4N/A9/30/201849-4N/A0N/A6/30/201854-3N/A3N/A3/31/201847-4N/A2N/A12/31/201747-3N/A6N/A9/30/201751-1N/A2N/A6/30/201750-1N/A2N/A3/31/2017591N/A-3N/A12/31/2016592N/A-6N/A9/30/2016582N/A-2N/A6/30/2016593N/A-2N/A3/31/2016634N/A9N/A12/31/2015613N/A5N/A9/30/2015635N/A5N/A6/30/2015655N/A5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: FDAの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: FDAの収益がItalian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: FDAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: FDAの収益がItalian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: FDAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: FDAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 02:07終値2026/05/21 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fidia S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Alberto FranceseIntesa Sanpaolo Equity ResearchSebastiano GrisettiIntesa Sanpaolo Equity Research
Major Estimate Revision • Oct 02Analysts lower revenue estimates to €26.0mThe 2020 consensus revenue estimate decreased from €33.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.98 for the same period. The Machinery industry in Italy is expected to see a 8.2% decline in net income next year. The consensus price target was lowered from €3.00 to €2.50. Share price is down by 1.2% to €2.43 over the past week.
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (446% increase in shares outstanding). Market cap is less than US$10m (€189.8k market cap, or US$223.4k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
分析記事 • Sep 26The Market Doesn't Like What It Sees From Fidia S.p.A.'s (BIT:FDA) Revenues Yet As Shares Tumble 27%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 27% in the last thirty days...
分析記事 • Aug 01Why Investors Shouldn't Be Surprised By Fidia S.p.A.'s (BIT:FDA) 34% Share Price PlungeFidia S.p.A. ( BIT:FDA ) shares have had a horrible month, losing 34% after a relatively good period beforehand. For...
分析記事 • May 26Investors Aren't Buying Fidia S.p.A.'s (BIT:FDA) RevenuesFidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...
New Risk • May 23New major risk - Revenue and earnings growthEarnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.5m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€3.88m market cap, or US$4.41m).
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€2.91m market cap, or US$3.25m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 11x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (over 11x increase in shares outstanding). Market cap is less than US$10m (€1.44m market cap, or US$1.63m).
Reported Earnings • Oct 25First half 2024 earnings released: €0.21 loss per share (vs €0.30 loss in 1H 2023)First half 2024 results: €0.21 loss per share. Revenue: €9.42m (up 4.8% from 1H 2023). Net loss: €7.22m (loss widened 246% from 1H 2023).
分析記事 • Oct 18Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% HidingTo the annoyance of some shareholders, Fidia S.p.A. ( BIT:FDA ) shares are down a considerable 34% in the last month...
分析記事 • Aug 29It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It LooksUnfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 40% in the last thirty days...
New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.17m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Market cap is less than US$10m (€9.17m market cap, or US$9.96m).
分析記事 • Jun 20Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% BounceFidia S.p.A. ( BIT:FDA ) shares have continued their recent momentum with a 28% gain in the last month alone. Still...
Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€19.8m market cap, or US$21.3m).
Reported Earnings • Jun 09Full year 2023 earnings released: €0.19 loss per share (vs €0.86 profit in FY 2022)Full year 2023 results: €0.19 loss per share (down from €0.86 profit in FY 2022). Revenue: €29.9m (up 21% from FY 2022). Net loss: €1.31m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
分析記事 • May 28Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)Key Insights The projected fair value for Fidia is €0.84 based on 2 Stage Free Cash Flow to Equity Current share price...
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.8m market cap, or US$16.8m).
New Risk • Apr 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 349% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€12.0m market cap, or US$12.8m).
New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 37% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (€3.10m market cap, or US$3.34m). Minor Risk Shareholders have been diluted in the past year (37% increase in shares outstanding).
分析記事 • Feb 13Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 31% in the last thirty days...
分析記事 • Dec 23Is Fidia (BIT:FDA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Oct 04Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren'tThere wouldn't be many who think Fidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.6% operating cash flow to total debt). High level of non-cash earnings (96% accrual ratio). Market cap is less than US$10m (€9.01m market cap, or US$9.81m). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Shareholders have been diluted in the past year (36% increase in shares outstanding).
Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Is New 90 Day High Low • Feb 13New 90-day high: €2.74The company is up 6.0% from its price of €2.58 on 13 November 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 15% over the same period.
Is New 90 Day High Low • Dec 30New 90-day low: €1.43The company is down 42% from its price of €2.46 on 01 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.
Is New 90 Day High Low • Dec 07New 90-day low: €2.08The company is down 22% from its price of €2.67 on 08 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 20New 90-day low: €2.15The company is down 22% from its price of €2.77 on 21 August 2020. The Italian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 14New 90-day low: €2.30The company is down 16% from its price of €2.73 on 16 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 19% over the same period.
Major Estimate Revision • Oct 02Analysts lower revenue estimates to €26.0mThe 2020 consensus revenue estimate decreased from €33.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.98 for the same period. The Machinery industry in Italy is expected to see a 8.2% decline in net income next year. The consensus price target was lowered from €3.00 to €2.50. Share price is down by 1.2% to €2.43 over the past week.
Is New 90 Day High Low • Sep 28New 90-day low: €2.40The company is down 16% from its price of €2.86 on 30 June 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.
Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €3.72m, with losses widening by 47% from the prior year. Total revenue was €38.1m over the last 12 months, down 31% from the prior year.
お知らせ • Sep 05Fidia S.p.A. to Report First Half, 2020 Results on Sep 11, 2020Fidia S.p.A. announced that they will report first half, 2020 results on Sep 11, 2020